210 related articles for article (PubMed ID: 30601074)
1. Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya.
Gerke C; Frantz PN; Ramsauer K; Tangy F
Expert Rev Vaccines; 2019 Apr; 18(4):393-403. PubMed ID: 30601074
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K
Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
Ramsauer K; Schwameis M; Firbas C; Müllner M; Putnak RJ; Thomas SJ; Desprès P; Tauber E; Jilma B; Tangy F
Lancet Infect Dis; 2015 May; 15(5):519-27. PubMed ID: 25739878
[TBL] [Abstract][Full Text] [Related]
4. Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
Ramsauer K; Tangy F
J Infect Dis; 2016 Dec; 214(suppl 5):S500-S505. PubMed ID: 27920181
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates.
Rossi SL; Comer JE; Wang E; Azar SR; Lawrence WS; Plante JA; Ramsauer K; Schrauf S; Weaver SC
J Infect Dis; 2019 Jul; 220(5):735-742. PubMed ID: 31053842
[TBL] [Abstract][Full Text] [Related]
6. Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.
Eldi P; Cooper TH; Liu L; Prow NA; Diener KR; Howley PM; Suhrbier A; Hayball JD
Mol Ther; 2017 Oct; 25(10):2332-2344. PubMed ID: 28720468
[TBL] [Abstract][Full Text] [Related]
7. Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.
Knuchel MC; Marty RR; Morin TN; Ilter O; Zuniga A; Naim HY
Hum Vaccin Immunother; 2013 Mar; 9(3):599-606. PubMed ID: 23324399
[TBL] [Abstract][Full Text] [Related]
8. A measles virus-based vaccine induces robust chikungunya virus-specific CD4
Schmitz KS; Comvalius AD; Nieuwkoop NJ; Geers D; Weiskopf D; Ramsauer K; Sette A; Tschismarov R; de Vries RD; de Swart RL
Vaccine; 2023 Oct; 41(43):6495-6504. PubMed ID: 37726181
[TBL] [Abstract][Full Text] [Related]
9. Chikungunya vaccines in development.
Schwameis M; Buchtele N; Wadowski PP; Schoergenhofer C; Jilma B
Hum Vaccin Immunother; 2016 Mar; 12(3):716-31. PubMed ID: 26554522
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus.
López-Camacho C; Kim YC; Blight J; Lazaro Moreli M; Montoya-Diaz E; Huiskonen JT; Kümmerer BM; Reyes-Sandoval A
Viruses; 2019 Apr; 11(4):. PubMed ID: 30987160
[TBL] [Abstract][Full Text] [Related]
11. Measles-derived vaccines to prevent emerging viral diseases.
Frantz PN; Teeravechyan S; Tangy F
Microbes Infect; 2018; 20(9-10):493-500. PubMed ID: 29410084
[TBL] [Abstract][Full Text] [Related]
12. Prime-boost immunization strategies against Chikungunya virus.
Hallengärd D; Lum FM; Kümmerer BM; Lulla A; Lulla V; García-Arriaza J; Fazakerley JK; Roques P; Le Grand R; Merits A; Ng LF; Esteban M; Liljeström P
J Virol; 2014 Nov; 88(22):13333-43. PubMed ID: 25210177
[TBL] [Abstract][Full Text] [Related]
13. Development of Vaccines for Chikungunya Fever.
Erasmus JH; Rossi SL; Weaver SC
J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179
[TBL] [Abstract][Full Text] [Related]
14. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
[TBL] [Abstract][Full Text] [Related]
15. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.
Roques P; Ljungberg K; Kümmerer BM; Gosse L; Dereuddre-Bosquet N; Tchitchek N; Hallengärd D; García-Arriaza J; Meinke A; Esteban M; Merits A; Le Grand R; Liljeström P
JCI Insight; 2017 Mar; 2(6):e83527. PubMed ID: 28352649
[TBL] [Abstract][Full Text] [Related]
16. Vaccine platform recombinant measles virus.
Mühlebach MD
Virus Genes; 2017 Oct; 53(5):733-740. PubMed ID: 28710608
[TBL] [Abstract][Full Text] [Related]
17. The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection.
Hu HM; Chen HW; Hsiao YJ; Wu SH; Chung HH; Hsieh CH; Chong P; Leng CH; Pan CH
Hum Vaccin Immunother; 2016 Jul; 12(7):1678-89. PubMed ID: 26901482
[TBL] [Abstract][Full Text] [Related]
18. A chikungunya fever vaccine utilizing an insect-specific virus platform.
Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
[TBL] [Abstract][Full Text] [Related]
19. Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development.
Rezza G; Weaver SC
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006919. PubMed ID: 30653504
[TBL] [Abstract][Full Text] [Related]
20. Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated
Carrau L; Rezelj VV; Noval MG; Levi LI; Megrian D; Blanc H; Weger-Lucarelli J; Moratorio G; Stapleford KA; Vignuzzi M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31270226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
